Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009.
You opened the Bulgarian affiliate back in 2009. How challenging was it to start from zero?
"All innovation needs to be supported with medical education and Amgen globally has been really active in this regard targeting those therapeutic areas in which it has strong expertise."
